New drug aims to tame rare inflammatory disease

NCT ID NCT05263934

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether a new drug, depemokimab, works as well as the current treatment mepolizumab for adults with a rare disease called EGPA, which causes inflammation of blood vessels. The study involves 163 participants and aims to see if depemokimab can help patients achieve remission while reducing their steroid use. Results are expected after 52 weeks of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: depemokimab (compared to mepolizumab)
What this could lead to: If depemokimab works as well as mepolizumab, it could offer a new treatment option for EGPA, potentially with less frequent dosing.
What could go wrong: This is a non-inferiority trial, so depemokimab may not be better than the existing drug. Results are still pending, and individual responses may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eosinophilic granulomatosis with polyangiitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS

Contacts and locations

Locations

GSK Investigational Site

Denver, Colorado, 80206, United States
GSK Investigational Site

Gainesville, Florida, 32610, United States
GSK Investigational Site

Rochester, Minnesota, 55905, United States
GSK Investigational Site

New York, New York, 10021, United States
GSK Investigational Site

Charlotte, North Carolina, 28211, United States
GSK Investigational Site

Pittsburgh, Pennsylvania, 15261, United States
GSK Investigational Site

La Plata, B1900, Argentina
GSK Investigational Site

San Miguel de Tucumán, T4000, Argentina
GSK Investigational Site

Graz, 8036, Austria
GSK Investigational Site

Santo André, 09060-870, Brazil
GSK Investigational Site

São Paulo, 4023900, Brazil
GSK Investigational Site

Toronto, Ontario, M5T 3A9, Canada
GSK Investigational Site

Toronto, Ontario, M5T 3L9, Canada
GSK Investigational Site

Beijing, 100005, China
GSK Investigational Site

Guangzhou, 510163, China
GSK Investigational Site

Hefei, 230001, China
GSK Investigational Site

Nanjing, 210006, China
GSK Investigational Site

Qingdao, 266071, China
GSK Investigational Site

Shanghai, 200032, China
GSK Investigational Site

Shenzhen, 518020, China
GSK Investigational Site

Wenzhou, 325000, China
GSK Investigational Site

La Roche-sur-Yon, 85925, France
GSK Investigational Site

Nantes, 44093, France
GSK Investigational Site

Paris, 75014, France
GSK Investigational Site

Freiburg im Breisgau, 79106, Germany
GSK Investigational Site

Minden, 32429, Germany
GSK Investigational Site

Ramat Gan, 52621, Israel
GSK Investigational Site

Bari, 70124, Italy
GSK Investigational Site

Brescia, 25123, Italy
GSK Investigational Site

Florence, 50134, Italy
GSK Investigational Site

Milan, 20132, Italy
GSK Investigational Site

Milan, 20162, Italy
GSK Investigational Site

Pavia, 27100, Italy
GSK Investigational Site

Pisa, 56126, Italy
GSK Investigational Site

Roma, 00128, Italy
GSK Investigational Site

Torrette AN, 60126, Italy
GSK Investigational Site

Treviso, 31100, Italy
GSK Investigational Site

Kanagawa, 247-8533, Japan
GSK Investigational Site

Kanagawa, 252-0392, Japan
GSK Investigational Site

Saitama, 350-8550, Japan
GSK Investigational Site

Tokyo, 162-8666, Japan
GSK Investigational Site

Tokyo, 181-8611, Japan
GSK Investigational Site

Groningen, 9713 GZ, Netherlands
GSK Investigational Site

Leiden, 2333 ZA, Netherlands
GSK Investigational Site

Gdansk, 80-952, Poland
GSK Investigational Site

Lodz, 90-153, Poland
GSK Investigational Site

Warsaw, 01-138, Poland
GSK Investigational Site

Lisbon, 1649-035, Portugal
GSK Investigational Site

Porto, 4099-001, Portugal
GSK Investigational Site

Gwangju, 61469, South Korea
GSK Investigational Site

Seoul, 05505, South Korea
GSK Investigational Site

Seoul, 06351, South Korea
GSK Investigational Site

Seoul, 06591, South Korea
GSK Investigational Site

Seoul, 3080, South Korea
GSK Investigational Site

Barcelona, 08035, Spain
GSK Investigational Site

Barcelona, 08036, Spain
GSK Investigational Site

Granada, 18014, Spain
GSK Investigational Site

Pamplona, 31008, Spain
GSK Investigational Site

Zaragoza, 50009, Spain
GSK Investigational Site

Malmö, SE-205 02, Sweden
GSK Investigational Site

Birmingham, B15 2GW, United Kingdom
GSK Investigational Site

Cambridge, CB2 2QQ, United Kingdom
GSK Investigational Site

London, SE1 7EH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.